Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2017 Nov 14

PMID 29129044

Citations 13

Authors

Jaehyun Lee

Yong Jae Shin

Kyoungmin Lee

Hee Jin Cho

Jason K Sa

Sang-Yun Lee

Seok-Hyung Kim

Jeongwu Lee

Yeup Yoon

Do-Hyun Nam

Affiliations

Soon will be listed here.

Abstract

Purpose: Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there are only few therapeutic agents that can effectively inhibit GBM invasion in a clinical framework. In an effort to address such challenges, we have generated anti-SEMA3A monoclonal antibody as a potential therapeutic antibody against GBM progression.

Materials And Methods: We employed public glioma datasets, Repository of Molecular Brain Neoplasia Data and The Cancer Genome Atlas, to analyze SEMA3AmRNA expression in human GBM specimens. We also evaluated for protein expression level of SEMA3A via tissue microarray (TMA) analysis. Cell migration and proliferation kinetics were assessed in various GBM patient-derived cells (PDCs) and U87-MG cell-line for SEMA3A antibody efficacy. GBM patient-derived xenograft (PDX) models were generated to evaluate tumor inhibitory effect of anti-SEMA3A antibody in vivo.

Results: By combining bioinformatics and TMA analysis, we discovered that SEMA3A is highly expressed in human GBM specimens compared to non-neoplastic tissues. We developed three different anti-SEMA3A antibodies, in fully human IgG form, through screening phage-displayed synthetic antibody library using a classical panning method. Neutralization of SEMA3A significantly reduced migration and proliferation capabilities of PDCs and U87-MG cell line in vitro. In PDX models, treatment with anti-SEMA3A antibody exhibited notable tumor inhibitory effect through down-regulation of cellular proliferative kinetics and tumor-associated macrophages recruitment.

Conclusion: In present study, we demonstrated tumor inhibitory effect of SEMA3A antibody in GBM progression and present its potential relevance as a therapeutic agent in a clinical framework.

Citing Articles

Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing.

van Bree N, Oppelt A, Lindstrom S, Zhou L, Boutin L, Coyle B Neuro Oncol. 2024; 27(3):779-794.

PMID: 39383211 PMC: 11889719. DOI: 10.1093/neuonc/noae210.

Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes.

Andryszak N, Kurzawa P, Krzyzaniak M, Ruchala M, Nowicki M, Izycki D Sci Rep. 2024; 14(1):1969.

PMID: 38263416 PMC: 10805734. DOI: 10.1038/s41598-024-51796-z.

Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination.

Hung Y, Hou Y, Hsu S, Wang L, Tsai Y, Shan Y Am J Cancer Res. 2023; 13(8):3417-3432.

PMID: 37693128 PMC: 10492129.

Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance.

Aiyappa-Maudsley R, McLoughlin L, Hughes T Int J Mol Sci. 2023; 24(17).

PMID: 37685898 PMC: 10487980. DOI: 10.3390/ijms241713093.

Semaphorins as Potential Immune Therapeutic Targets for Cancer.

Jiang J, Zhang F, Wan Y, Fang K, Yan Z, Ren X Front Oncol. 2022; 12:793805.

PMID: 35155237 PMC: 8830438. DOI: 10.3389/fonc.2022.793805.

References

Kigel B, Varshavsky A, Kessler O, Neufeld G . Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One. 2008; 3(9):e3287. PMC: 2538586. DOI: 10.1371/journal.pone.0003287. View

Rivera L, Bergers G . Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity. Cancer Cell. 2013; 24(6):687-9. PMC: 4243836. DOI: 10.1016/j.ccr.2013.11.014. View

Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M . Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013; 24(6):695-709. DOI: 10.1016/j.ccr.2013.11.007. View

Neufeld G, Sabag A, Rabinovicz N, Kessler O . Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med. 2012; 2(1):a006718. PMC: 3253028. DOI: 10.1101/cshperspect.a006718. View

Acevedo L, Barillas S, Weis S, Gothert J, Cheresh D . Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008; 111(5):2674-80. PMC: 2254547. DOI: 10.1182/blood-2007-08-110205. View

Muller M, Giese N, Swiercz J, Ceyhan G, Esposito I, Hinz U . Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer. 2007; 121(11):2421-33. DOI: 10.1002/ijc.22949. View

Sliwkowski M, Mellman I . Antibody therapeutics in cancer. Science. 2013; 341(6151):1192-8. DOI: 10.1126/science.1241145. View

Cerani A, Tetreault N, Menard C, Lapalme E, Patel C, Sitaras N . Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013; 18(4):505-18. DOI: 10.1016/j.cmet.2013.09.003. View

Luo Y, Raible D, Raper J . Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell. 1993; 75(2):217-27. DOI: 10.1016/0092-8674(93)80064-l. View

10.

Herbst R, Shin D . Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002; 94(5):1593-611. DOI: 10.1002/cncr.10372. View

11.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

12.

Bagci T, Wu J, Pfannl R, Ilag L, Jay D . Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene. 2009; 28(40):3537-50. DOI: 10.1038/onc.2009.204. View

13.

Kruger R, Aurandt J, Guan K . Semaphorins command cells to move. Nat Rev Mol Cell Biol. 2005; 6(10):789-800. DOI: 10.1038/nrm1740. View

14.

Yang H, Kang K, Chung J, Shim H . Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Mol Cells. 2009; 27(2):225-35. DOI: 10.1007/s10059-009-0028-9. View

15.

Linger R, Keating A, Earp H, Graham D . TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008; 100:35-83. PMC: 3133732. DOI: 10.1016/S0065-230X(08)00002-X. View

16.

Treps L, Edmond S, Harford-Wright E, Galan-Moya E, Schmitt A, Azzi S . Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 2015; 35(20):2615-23. DOI: 10.1038/onc.2015.317. View

17.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

18.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin N . Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. DOI: 10.1016/j.ccr.2006.03.030. View

19.

Solinas G, Germano G, Mantovani A, Allavena P . Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009; 86(5):1065-73. DOI: 10.1189/jlb.0609385. View

20.

Reardon D, Wen P . Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006; 11(2):152-64. DOI: 10.1634/theoncologist.11-2-152. View